Empagliflozin More Effective to Reduce Risk of Heart Failure Hospitalization vs DPP-4 Inhibitors, GLP-1 Receptor Agonists
ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.
Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial
ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.
Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.
A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
DiabetesWise Pro lets clinicians compare diabetes devices for a specific patient and provides the steps for ordering the device based on insurance type.
CGM News: FreeStyle Libre 3 Cleared by FDA for Persons Aged 4 Years and Older with Diabetes
The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.
Gen Z Youth Want Their Physicians to Ask Them about Social Determinants of Health
A new survey of youth aged 14 to 24 years provides significant support for integrating questions about social needs into routine clinical care.
Time to Benefit Following Intensive BP Reduction in Adults Aged 60 Years and Older
The first study of its kind found that intensive blood pressure control may be most beneficial in older adults with life expectancy greater than 3 years vs less than 1 year.
Treatment Gap: In Patients with ASCVD, Low Use of Statins, High-intensity Statins Persists
One-half of more than 600 000 patients with ASCVD were not prescribed statins at all and only 22.5% were taking a high intensity statin, according to a recent study.
Pfizer Wins Fast Track Designation for Potential NASH Drug Combination
Early phase 2a study results of a combination of the 2 agents previously evaluated as NASH monotherapies led to the FDA award for Pfizer.
Risk for HF Hospitalization in Type 2 Diabetes Lower with First-line SGLT-2 Inhibitor vs Metformin
Initiating T2D treatment with an SGLT2 inhibitor reduced risk for heart failure hospitalization compared to metformin in a new study; cardiovascular outcomes were similar.
National Kidney Foundation Urges USPSTF to Prioritize Screening Recommendation for CKD
The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."
Metformin, Lifestyle in Prediabetes May Reduce Risk of T2D but Not Major CV Events
Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.
FDA Grants EUA for At-home Triple Test: COVID-19, Influenza, RSV
The Labcorp home test, available without a prescription, is delivered overnight and includes a return envelope. Results are available in 1-2 days.
Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
Compare, contrast, price shop, prescribe. DiabetesWise Pro developer Korey Hood, PhD, highlights the tool all primary care clinicians should try.
CDC Greenlights COVID-19 Booster for Children Aged 5 to 11 Years
The CDC is encouraging parents of children in this age group to first finish a primary vaccination series, saying only 28% now are in that category.
Early, Consistent Glucose Control May Be Key to CVD Risk Reduction in Type 2 Diabetes: A Primary Care Analysis
In adults with type 2 diabetes seen in primary care, lowering glucose substantially during the first 12 months post-diagnosis decreased risk for future MACE.
SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.
Majority of Asthma Patients Prescribed Dupilumab vs Other Biologics as Initial Rx, According to Extensive Real-world Analysis
ATS 2022: Dupilumab is often the first biologic agent prescribed for moderate-to-severe asthma according to analysis of a US database comprising more than 100 million patients.
FDA Authorizes Pfizer-BioNTech COVID-19 Booster for Children Aged 5 to 11 Years
Children aged 5 to 11 years can receive a single dose booster shot 5 months after completing a primary 2-dose series of the Pfizer COVID-19 vaccine, FDA says.
Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim
ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.
Novel Fixed-dose Albuterol-Budesonide Inhaler Significantly Reduced Exacerbation Risk in Severe Asthma
ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.
First-in-Class Tirzepatide Wins FDA Approval for Treatment of Type 2 Diabetes
Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.
Objective Confirmation of Asthma Diagnosis Often Missing in Primary Care, Study Suggests
ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.
Multiancestry Genetic Study of T2D Expands Potential for Risk Assessment, Treatment
A study of the most genetically diverse collection of DNA from persons with T2D yields 40 new potentially causative genes that may transcend ancestry.
Half of Hospitalized COVID-19 Survivors Report at Least 1 Enduring Symptom at 2 Years
Long COVID symptoms affected 55% of persons hospitalized for the infection, regardless of severity of initial illness, report a Chinese team of investigators.
Patient-centered Treatment for Obesity: Guidelines from the Canadian Obesity Society
The Canadian Obesity Society advocates for a therapeutic approach to obesity that removes stigma, focuses on individual patient goals, and favors body health over body weight.
Tailored Diabetes Risk Assessment May Reduce Racial/Ethnic Disparities in Diagnosis
Lowering thresholds for BMI value and age of first diabetes screening among large US minority populations could greatly increase rates of diagnosis and improve care.
Interview: Delay in Second-line T2D Treatment Among Younger US Veterans Sparks Investigator Concern
HbA1c levels over time were found higher at initiation of second-line treatment in veterans aged 55 years and younger, a trend unsettling to a new study's lead author.
Obesity Rose Disproportionately Among Low-income Youth During Early COVID-19
The proportion of overweight, obesity, or severe obesity increased from 38% to 45% among 4500 young people seen in a primary care network where most receive public insurance.
